Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Santhera Pharmaceuticals Holding AG's revenue per share for the
six
months ended in Dec. 2025 was CHF4.01.
Santhera Pharmaceuticals Holding AG's revenue per share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF5.89.
During the past 12 months, the average Revenue Per Share Growth Rate of Santhera Pharmaceuticals Holding AG was 72.60% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 69.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
XSWX:SANN'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -73.9 Med: 12.8 Max: 288.3
Current: 69.1
During the past 13 years, Santhera Pharmaceuticals Holding AG's highest 3-Year average Revenue Per Share Growth Rate was 288.30% per year. The lowest was -73.90% per year. And the median was 12.80% per year.
XSWX:SANN's 3-Year Revenue Growth Rate is ranked better than 88.17% of 769
companies
in the Biotechnology industry
Industry Median: 3
vs XSWX:SANN: 69.10
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Santhera Pharmaceuticals Holding AG Revenue per Share Related Terms
Santhera Pharmaceuticals Holding AG Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG Revenue per Share Chart
XSWX:SANN vs VRTX, REGN, RVMD: Revenue per Share Comparison
For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santhera Pharmaceuticals Holding AG PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's PS Ratio distribution charts can be found below:
* The bar in red indicates where Santhera Pharmaceuticals Holding AG's PS Ratio falls into.
Santhera Pharmaceuticals Holding AG Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF5.89
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG (XSWX:SANN) has a Revenue per Share of CHF5.89 as of Dec. 2025. Revenue per share equals the per-share value of a company's sales. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #91 out of 769 companies in the Biotechnology industry, placing it in the top 11.8%.
Is Santhera Pharmaceuticals Holding AG's Revenue per Share too high?
Santhera Pharmaceuticals Holding AG's current Revenue per Share is CHF5.89. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #91 out of 769 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's Revenue per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #91 out of 769 companies for Revenue per Share. This places Santhera Pharmaceuticals Holding AG in the top 12% of its industry — outperforming the majority of peers. The industry median Revenue per Share is 3.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 3.00, based on 769 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. For the Biotechnology industry, the median Revenue per Share is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santhera Pharmaceuticals Holding AG's current Revenue per Share is CHF5.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (XSWX:SANN) is currently considered Possible Value Trap. The stock's GF Value™ is CHF23.61, compared to a current price of CHF14.02 — trading 40.6% below its estimated fair value. The current Revenue per Share is CHF5.89. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (XSWX:SANN), the current Revenue per Share is CHF5.89 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santhera Pharmaceuticals Holding AG (XSWX:SANN) Overvalued in 2026?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued.
The current stock price of CHF14.02 is trading 40.6% below its estimated GF Value™ of CHF23.61.
GuruFocus considers Santhera Pharmaceuticals Holding AG to be Possible Value Trap.
Key valuation signals for XSWX:SANN:
Revenue per Share: CHF5.89
GF Value™: CHF23.61 vs. price of CHF14.02 (40.6% below fair value)
No single metric tells the full story. See the XSWX:SANN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
34GF Score
Get the complete analysis for XSWX:SANN
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SANN has been successfully added to your 
